Home   Business   Article

Repositive repositions into Science Exchange




Some of the Repositive team at their Betjeman House base. From left are Richard Shaw, Alicia Caunter, Justyna Wiraszka and Cintia Palu. Picture: Keith Heppell
Some of the Repositive team at their Betjeman House base. From left are Richard Shaw, Alicia Caunter, Justyna Wiraszka and Cintia Palu. Picture: Keith Heppell

Repositive has made its directory of 5,300 preclinical cancer models available on Science Exchange.

The Cambridge company says the collaboration with the widely used technology platform for outsourced R&D will broaden access to its tools.

The Respositive genomic data platform catalogues the metadata for PDXandCDX models, syngeneic andhumanisedmouse models, GEMMs, cell lines and organoids from specialist oncology CROs around the world.

The involvement with Science Exchange means that via its comprehensive, specialist and confidential cancer models scout service, Repositive’s team of molecular biology and bioinformatics experts are on hand to “provide model recommendations tailored to each project’s precise requirements and search not only Repositive’s directory of models, but also its extended CRO network containing over 20,000 models”.

“We’re delighted to be collaborating with Science Exchange to increase access to our cancer models directory and specialist cancer models scout service among the translational oncology community,” said Fiona Nielsen, CEO at Repositive.

“The streamlined project management, hassle-free invoicing and simple payment options offered by Science Exchange supports Repositive’s mission to make it quicker and easier for pharma and biotech researchers to access the preclinical cancer models they need to accelerate the development of effective cancer therapies.”

Repositive’s journey began in 2016 with the announcement of the development of the Global PDX Directory to act as a global data broker and network for oncology researchers and PDX model developers.

In 2018 the PDX Directory was expanded to become the cancer models platform, and its scope was broadened to incorporate CDX, syngeneic and humanised mouse models, as well as 3D in vitro systems and other popular translational cancer models that support immuno-oncology and combination therapies.

The Cambridge Independent Science and Technology Awards 2018. Highly Commended CEO of the Year is Fiona Nielsen.Picture: Richard Marsham
The Cambridge Independent Science and Technology Awards 2018. Highly Commended CEO of the Year is Fiona Nielsen.Picture: Richard Marsham

After partnering with 19 specialist CROs across the globe, including Antineo, Shanghai LIDE and Xentech, Repositive’s directory is now the world’s largest global directory of preclinical cancer models.

In October 2018 Repositive announced the launch of a cancer models scout service: industry researchers working in translational oncology can ask Repositive to conduct an expert, tailored and confidential search to find the right cancer model for the hypothesis they are looking to test using its world-leading directory and extensive CRO partner network.

Science Exchange, meanwhile, has developed a technology platform that is “the fastest, easiest way for scientists to discover, order, manage and pay for outsourced R&D services”.

The secure, online platform connects scientists in research-intensive industries, such as pharmaceuticals, biotechnology, consumer health, and agriscience, with more than 7,000 services from 2,500 qualified, precontracted research providers.

Science Exchange solves the challenges of outsourced R&D – like provider qualification, administrative delays, and data security/privacy – by automating collaborative tasks, such as managing quotes, tracking projects, and processing payments.


Read more


This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More